Loading patent…
Assignee11949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
InventorsJean I. TCHERVENKOV, Ahmed FOUDA, Steven PARASKEVAS, Sarita NEGI, Jonathan COOLS-LARTIGUE
Estimating the term…
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
(canceled)
A method of preventing or treating a disease, autoimmune disease or antibody mediated rejection in a patient in a patient in need thereof, wherein said disease is characterized by an elevated neutrophil to lymphocyte ratio (NLR) in the peripheral blood of the patient, which comprises administering to said patient a therapeutically effective amount of a ROR inverse agonist, its pharmaceutically acceptable salt or stereoisomers thereof, wherein said neutrophils express nuclear receptors (RORs) alpha (RORα or RORA) or gamma (RORC, RORy or RORγt).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
13-25. (canceled)
27-39. (canceled)
41-44. (canceled)
Dependencies are inferred from the claim text.